GlassScriptPhysician profile
Ramesh Sabapathi
NPI 1730118993
$1,388.27
in general payments reported to CMS, 2019-2025
23 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $30.31 · 2021: $82.57 · 2022: $287 · 2023: $164 · 2024: $342 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.26 |
| Education | $169.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $307.13 | 2023-2025 | Austedo Xr, Austedo Xr |
| Urovant Sciences INC | $277.61 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $139.00 | 2019 | |
| Lilly USA, LLC | $81.48 | 2023-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $80.34 | 2019-2024 | Breztri |
| Sunovion Pharmaceuticals INC. | $63.62 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $49.55 | 2019 | |
| Neurelis, INC. | $48.46 | 2022-2024 | Valtoco |
| Smith+Nephew, INC. | $44.15 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.63 | 2023-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $33.79 | 2024 | Rexulti |
| Neurocrine Biosciences, INC. | $30.20 | 2023 | Ingrezza |
| Sumitomo Pharma America, INC. | $27.58 | 2024 | Gemtesa |
| Exact Sciences Corporation | $20.89 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $19.91 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $19.85 | 2024 | |
| Eisai INC. | $19.30 | 2020 | |
| Acadia Pharmaceuticals INC | $17.80 | 2019 | |
| Glaxosmithkline, LLC. | $16.16 | 2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $13.94 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.52 | 2019 | |
| Sun Pharmaceutical Industries INC. | $11.35 | 2021 | |
| Merck Sharp & Dohme LLC | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Sabapathi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.